ATPW
CPRX

Ashton Thomas Private Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$948K Buy
38,292
+23,611
+161% +$562K 0.02% 548
2025
Q4 		$343K Buy
14,681
+315
+2% +$7.02K 0.01% 776
2025
Q3 		$283K Sell
14,366
-1,645
-10% -$33.8K 0.01% 819
2025
Q2 		$347K Buy
16,011
+2,997
+23% +$70.7K 0.01% 648
2025
Q1 		$316K Buy
13,014
+899
+7% +$20.2K 0.01% 643
2024
Q4 		$253K Buy
12,115
+276
+2% +$5.93K 0.01% 681
2024
Q3 		$235K Buy
11,839
+84
+0.7% +$1.56K 0.01% 558
2024
Q2 		$182K Buy
11,755
+342
+3% +$5.32K 0.01% 586
2024
Q1 		$182K Buy
11,413
+1,014
+10% +$15.3K 0.01% 577
2023
Q4 		$175K Sell
10,399
-190
-2% -$2.6K 0.01% 562
2023
Q3 		$124K Buy
10,589
+190
+2% +$2.54K 0.01% 550
2023
Q2 		$140K Buy
+10,399
New +$150K 0.01% 558

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ashton Thomas Private Wealth's CPRX Position: Q1 2026 in Review

Ashton Thomas Private Wealth increased its Catalyst Pharmaceutical (CPRX) stake by 161% in Q1 2026, buying an estimated $562K and bringing the position to 38,292 shares worth $948K. The position accounts for 0.02% of the portfolio, ranked #548.

Ashton Thomas Private Wealth first reported a position in CPRX in Q2 2023 and has held it in 12 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Ashton Thomas Private Wealth held 38,292 shares of Catalyst Pharmaceutical worth $948K as of Q1 2026.
  • Ashton Thomas Private Wealth bought 23,611 Catalyst Pharmaceutical shares in Q1 2026, an estimated $562K.
  • Catalyst Pharmaceutical made up 0.02% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #548 holding.
  • Ashton Thomas Private Wealth first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.